MiR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

ABSTRACT: The development of drug resistance is still a major impediment for the successful treatment of cancer, such as advanced stage ovarian cancer, which has a 5-year survival rate of only 30%. The molecular processes that contribute to resistance have been extensively studied, however, not much is known about the role of microRNAs. We compared microRNA expression profiles of three isogenic cisplatin sensitive and resistant cell line pairs. The only microRNA that was consistently downregulated (FDR = 0.000) in all resistant cell lines was miR-634. We investigated the effects of miR-634 modulation in ovarian cancer cell lines and patient derived tumor cells. Overexpression of miR-634 gave rise to a modest G1 phase block and enhanced apoptosis. Furthermore, miR-634 resensitized resistant ovarian c

ORGANISM(S): Homo sapiens

SUBMITTER: Erik Wiemer 

PROVIDER: E-GEOD-54665 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress